ERBB2 and breast carcinoma: Caution is required when relying solely on pCR as a surrogate endpoint in clinical trials since this may not fully reflect long-term outcomes in the real-world setting, especially in ER+ErbB2- breast cancer, which is known for late recurrences [15].